Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
The Motley Fool ·
Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
1 sources · 1 articles · updated 2026-11-08 16:15 UTC · business